Pharmaceuticals

Fighting Diseases

A swimmer is swimming underwater in a pool.
Latest News
February 29, 2024
Heiko Schipper to leave the company on April 30, 2024
Julio Triana appointed to Board of Management of Bayer AG and President of the Consumer Health Division
February 29, 2024
Elections at the Annual Stockholders' Meeting on April 26, 2024:
Bayer aims to further extend expertise in Supervisory Board
February 26, 2024
Not intended for UK Media
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
February 19, 2024
Bayer plans to amend its dividend policy to reduce debt
January 24, 2024
Not intended for U.S. and UK Media
Application for regulatory approval of Aflibercept 8 mg accepted in China
January 18, 2024
Not intended for U.S. and UK Media
New Eylea™ 8 mg approved in Japan
January 17, 2024
Board of Management and employee representatives agree on future direction
Bayer aims to sustainably improve performance with new organization
January 08, 2024
Not intended for U.S. and UK Media
New Eylea™ 8 mg approved in EU
January 08, 2024
Not intended for UK Media
Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies
January 04, 2024
Not intended for UK Media
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
November 19, 2023
Not intended for U.S. and UK Media
OCEANIC-AF study stopped early due to lack of efficacy
November 08, 2023
Bayer Group:
Third quarter below prior year as expected – Group outlook confirmed
October 16, 2023
6th International Rice Congress in Manila, Philippines:
Bayer introduces agricultural system for direct-seeded rice with potential to reduce greenhouse gas emissions and water use by up to 40 percent
October 05, 2023
Not intended for UK Media
Bayer to partner with Twist Bioscience to accelerate drug discovery
September 21, 2023
More than 70% of farmers have already seen large impacts of climate change on their farm, new global research across 8 countries reveals
September 18, 2023
Not intended for UK Media
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
August 29, 2023
Gene Editing: Pairwise and Bayer start new five-year multi-million Dollar collaboration to further advance short-stature corn
August 28, 2023
Not intended for UK Media
BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
August 21, 2023
Heike Prinz appointed to Board of Management of Bayer AG
August 10, 2023
Not intended for U.S. and UK Media – Two-year topline results from the pivotal study PULSAR:
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
August 08, 2023
Bayer Group:
Second quarter impacted by declines in glyphosate business
July 24, 2023
Bayer lowers full-year outlook
June 29, 2023
Not intended for U.S. and UK Media
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
June 22, 2023
Not intended for U.S. and UK Media
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
June 20, 2023
Crop Science Innovation Summit 2023:
Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres
May 23, 2023
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer issues new senior bonds with a volume of 3 billion euros
May 16, 2023
Not intended for UK Media
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
May 11, 2023
Bayer Group business performance in the first quarter of 2023:
Slow start to the year as expected
May 10, 2023
Not intended for U.S. and UK Media
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
April 28, 2023
CEO Werner Baumann at the Annual Stockholders’ Meeting:
“Bayer has excellent prospects for the future”
April 05, 2023
Bayer to invest a total of 60 million euros in its Ukrainian seed production site
April 03, 2023
Internationally renowned experts form independent Bayer Bioethics Council
Bayer establishes Bioethics Council
March 21, 2023
UN 2023 Water Conference:
Bayer pledges to help tackle global water crisis with new water strategy
March 20, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
March 01, 2023
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer
March 01, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for marketing authorization in Japan
February 28, 2023
Fiscal 2022
Bayer: Significant growth in sales and earnings
February 27, 2023
Not intended for U.S. and UK Media
Nubeqa™ approved for additional indication in Japan
February 10, 2023
Not intended for U.S. and UK Media
Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
February 06, 2023
Not intended for U.S. and UK Media
Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU
January 31, 2023
Bayer to distribute pheromone-based biological crop protection solutions from M2i Group
January 27, 2023
Not intended for U.S. and UK Media
CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
January 10, 2023
Not intended for U.S. and U.K. Media
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
December 16, 2022
Not intended for U.S. and UK Media
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
December 14, 2022
Bayer recognized as leader on climate change for fifth consecutive year
November 29, 2022
Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
November 11, 2022
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for Eylea™ in the EU for treatment of preterm infants with retinopathy of prematurity
November 08, 2022
Third quarter of 2022
Bayer with continued strong performance
October 17, 2022
Not intended for U.S. and UK Media
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy
October 05, 2022
Bayer completes sale of its Environmental Science Professional business to Cinven